New hope for tough pancreatic cancers: boosting chemo with immune power
NCT ID NCT03983057
Summary
This study tested if adding an immunotherapy drug (Anti-PD-1 antibody) to standard chemotherapy could better control pancreatic cancer. It involved 392 patients whose cancer was borderline or locally advanced, meaning surgery was difficult. Researchers compared the standard chemo alone to the chemo-plus-immunotherapy combination to see which helped patients live longer without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
Conditions
Explore the condition pages connected to this study.